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Summary Serum dopamine-fl-hydroxylase (DBH) activity has been reported to be raised in some patients
with neuoblastoma but this has been challenged. We have studied serum DBH levels on 26 children with
neuroblastoma and 58 age-matched controls. Only in 2 patients were the levels higher than in the controls,
and then only transiently. In both, the rise in DBH levels could be accounted for by the transfusion of adult
blood. Serum DBH levels in children with neuroblastoma were unrelated to the response of this neoplasm to
treatment or to urinary catecholamine output and thus are unlikely to have any value in diagnosis or as a
marker of tumour activity.
The main pathways by which catecholamines are
synthesized and metabolised are shown in Figure 1.
The enzyme DBH catalyses the last step in the
biosynthesis of noradrenaline and is found in
chromaffin tissue and in the synaptic vesicles of
sympathetic tissue. In vitro studies demonstrated the
coupled proportional release of noradrenaline and
DBH from sympathetic nerves by a process of
exocytosis (Weinshilboum et al., 1971). The main
source of serum DBH in the rat is the adrenergic
neuron whence it is discharged during sympathetic
activity (Weinshilboum & Axelrod, 1971;
Weinshilboum, 1978). There is very little
information available on the source, half-life, and
fate of human serum DBH (Weinshilboum, 1978).
Neuroblastomas are composed of primitive cells
derived from the neural crest. They form and
discharge noradrenaline and its precursors DOPA
and dopamine. These substances are metabolised
both within the tumour and elsewhere, and the
metabolites, together with some free catecholamines
are excreted in excess in the urine. Tumours
producing predominantly noradrenaline and its
metabolites have a more favourable prognosis
(Gitlow et al., 1973; Laug et al., 1978). However, the
measurement of these metabolites in urine is time-
consuming and the common methods lack specifity.
Since in vitro noradrenaline production is associated
with DBH release, elevated serum DBH levels may
be expected to occur in children with
neuroblastoma, and, if present, carry diagnostic and
prognostic value. The spectrophotometric assay of
serum DBH utilizes optimum conditions for
measurement of enzyme activity. It is specific,
relatively quick and requires only small volumes of
serum, making it suitable for routine use in the
hospital laboratory (Weinshilboum, 1978). Elevated
serum DBH levels have been reported in children
with neuroblastoma (Goldstein et al., 1972; Rockson
et al., 1976), but a recent study has challenged these
observations (Brewster & Berry, 1979).
We have studied serum DBH levels of
neuroblastoma patients and age-matched controls
and have analysed the results in relation to age,
clinical status, and urinary catecholamine output.
Patients and methods
Patients
Fourteen boys and 12 girls with neuroblastoma,
aged from one month to 8 years were studied.
Serum DBH and urinary catecholamine excretion
were measured, in some patients serially. Clinical
staging was performed using the method of Evans
et al. (1971) and the clinical status of each patient
was recorded.
The control subjects were age-matched groups of
58 children who were undergoing investigations
necessitating venepuncture for other disorders at the
same hospital: alimentary tract and nutritional (9),
cardiovascular (4), central nervous system (7),
haematological (2), respiratory (2) and urinary tract
disorders (13); neoplasms other than neuroblastoma
(15) and miscellaneous disorders (6). Serum DBH
only was determined on these groups.
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Venous blood specimens were centrifuged at
3,000r.p.m. and the sera were stored at -20°C until
assayed. Serum DBH activity was measured by a
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Figure 1 The major pathways of catecholamine metabolism.
modification of the spectrophotometric assay
developed by Nagatsu & Udenfriend (1972), and
expressed in iul-. (liul-V=lpMmin 1- of
serum). Aliquots of 40p1 serum were diluted to
400p1 with cold water to enhance enzyme activity
and then were preincubated at 37°C for 5min. The
enzyme reaction was initiated by the addition of
600pl of warmed substrate cocktail containing
200pl N-ethylmaleimide (0.2 Ml 1), 100pl sodium
acetate (2 M-1), 50pl tyramine (0.4 M-1), 50pl
sodium fumarate (0.2Ml-1), 50pl pargyline
(2OmMl-1), 50pl catalase (2mgml-1), 50pl
ascorbic acid (0.2Ml-1), and 50pl distilled water.
The final pH of the cocktail was adjusted to 5.0
with glacial acetic acid. After 30min at 37°C the
reaction was terminated by the addition of 200p1
cold tricholoroacetic acid. After centrifugation 1 ml
of the acidified mixture was transferred to a small
column (300p1 bed volume) of Dowex-50 (H+, 200-
400 mesh). After washing with 2ml distilled water
the adsorbed reaction product octopamine was
eluted with 2ml ammonia (4moll-1). Octopamine
in the eluate was converted to p-
hydroxybenzaldehyde and quantified (Nagatsu &
Udenfriend 1972). Blank values were obtained by
substituting water for enzyme. Specimens with
activity less than 1 iu1-1 were repeated using a
more sensitive technique (Kato et al., 1974). All
measurements were performed in duplicate. Control
adult sera were used to determine assay precision.
Mean values of 40.4+0.85iul-1 (sd for 10 samples)
for intra-batch analysis, and 33.4+0.93iul-1 (sd for
10 batches) for inter-batch analysis were obtained.
Urinary catecholamines and metabolites
Twenty four-hour urine specimens were collected
into bottles containing 5ml of 5mol1-'
hydrochloric acid. The following were excluded
from the child's diet during collections and the
preceding day: bananas, chocolate, cocoa, ice-cream,
nuts, food flavoured with vanilla, sweets and drugs
such as sympathomimetics, chloral hydrate and
salicylates. The quantitative determinations of total
catecholamines (Varley, 1967), total metadrenalines
(Pisano, 1960), and 4-hydroxy-3-methoxy-mandelic
acid (HMMA) (Pisano et al., 1962), were performed
at the Department of Clinical Chemistry, Royal
Manchester Children's Hospital, and the results
were interpreted by reference to the normal ranges
established in that laboratory by 95% confidence
limits.
Results
The age, stage, DBH levels, urinary catecholamine
excretion and clinical status of the neuroblastoma
patients are shown in Table I. Control subjects
were undergoing investigations for a variety of
disorders.
The serum DBH activities of the neuroblastoma
patients were similar to those of age-matched
controls (Table II). Studies in our laboratory have
shown that DBH rises with age to approach adult
values (0-100iul-, mean 29iul'-) at around 7
years, with no difference between the sexes.SERUM DOPAMINE ,B HYDROXYLASE IN NEUROBLASTOMA 117
Table I Urinary excretion of catecholamines and metabolites (pgmg- 1 creatinine) in neuroblastoma patients
Total
Age DBH Catecholamines Total Clinical
Case (years) Stage IU 1 -' (as Dopamine) metadrenalines HMMA Status Course
1 0.1 I 2.1 1.20 2.80 8.0 NED Died 1.7yr.
2 0.2 IVS 66.3
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
0.7
0.7
0.8
0.8
1.0
1.0
1.3
1.2
1.5
1.8
2.0
2.0
3.0
3.7
3.7
4.0
4.2
4.2
4.4
4.4
4.4
4.8
5.0
5.0
5.5
7.2
IV
I
IV
IV
IV
IV
IV
IV
III
IV
IV
IV
IV
III
IV
IV
IV
III
IV
I.V
III
IV
IV
IV
2.7
0.4
2.1
2.8
2.3
9.7
0.9
2.4
4.9
2.4
11.9
9.7
7.2
3.0
7.7
7.3
7.9
10.4
9.8
12.0
15.1
6.6
0.3
19.4
9.30T
9.60T
2.77
9.60T
16.10T
12.00T
12.70T
11.201
3.301
1.20
9.20T
2.10
0.31
18.80T
1.60
14.60T
2.39t
20.30T
17.40T
15.00T
3.45T
12.90T
26.301
0.67
1.10
190.00t 447.0T Disease
1.20 15.0 Disease
1.14 9.8 NED
1.03 10.7 Disease
0.90 9.3 Disease
Disease
Disease
0.85 20.6T Disease
6.70T 117.0T
0.77 5.1
14.4T
0.77 4.4
2.60 16.6T
10.30T 32.4t
5.20T 52.901
23.00T 22.00T
0.48 5.90
1.60 7.70
3.90t 92.00T
7.30T 130.00T
3.70T 9.50T
14.40T 68.30T
1.60 5.70
1.70 4.70
0.72 11.201
0.65 6.75
1.06 12.401
Disease
Disease
Disease
NED
Disease
Disease
Disease
Disease
NED
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
NED
Disease
Intestinal obstruction
Died 0.8 yr. Bleeding
oesophageal varices.
Residual disease
Died 1.2 yr. NBL
NED 5 yr.
Died 0.9 yr. NBL
Died 1.9 yr. NBL
Died 1.3 yr. NBL
Died 1.8 yr.
Pneumocystis carinii
pneumonia; residual
disease
Died 1.7 yr. NBL
Died 1.8 yr. NBL
NED 7.8 yr.
Died 2.4 yr. NBL
Died 3.4 yr. NBL
Died 4.4 yr. NBL
Died 3.8 yr. NBL
NED 7.8 yr.
Died 4.3 yr. NBL
Died 4.8 yr. NBL
Died 5.8 yr. NBL
Died 5.6 yr. NBL
Died 5.4 yr. NBL
Died 5.8 yr. NBL
Died 5 yr. NBL
Died 6.2 yr. NBL
Died 5.8 yr. NBL
Died 8.7 yr. NBl
NED=No evidence of disease.
NBL =Neuroblastoma.
T =Level above 95% confidence limits of controls.118 B.B. ELDEEB et al.
Table II Serum DBH levels (iu 1-')
Neuroblastoma Neuroblastoma
Age Controls Patients with disease Patients without disease
(years) No. Range Mean No. Range Mean No. Range Mean
<2 17 0-12.7 3.12 8 0.9-9.7 4.0 2 0.4-2.1 1.25
2-4 12 2.7-18.5 12.9 4 7.2-11.9 9.6 2 3.0-4.9 3.95
4-6 12 6.4-29.3 14.7 8 6.6-15.1 9.5 1 0.2
6-9 17 4.0-35.0 17.0 1 19.4 0
58 21 5
Regression analysis of DBH activities of controls
and neuroblastoma patients showed progressive
elevation with age (Figure 2) but no significant
difference between the two groups by analysis of
covariance (P= >0.5). Similarly, a successfully
treated neuroblastoma patient (case 4) was noted to
have increasing serum DBH activity as she was
followed from the age of 9 months to 3.7 years
(Table III).
Five control subjects had high DBH levels
(Figure 2). Acute stress may explain this
(Weinshilboum, 1978) as these patients were
hospitalised for suspected intestinal obstruction,
pneumonia, convulsions, parental abuse and
investigation of ovarian teratoma.
Serial determinations of serum enzyme levels were
obtained for 8 neuroblastoma patients extending
over periods of 4 months to 3 years (Table III). No
changes in enzyme levels were noted in relation to
disease activity, nor to changes in urinary
catecholamine excretion, which corresponded to
disease status. However, DBH activity was affected
by external factors. For example, in a child with
neuroblastoma (Case 6), DBH levels increased
transiently on the day after partial removal of the
tumour and rose again at the age of 20 months. We
attributed the postoperative elevation to transfusion
with adult blood containing higher DBH levels.
Pooled plasma from 5 units of whole blood had a
mean DBH activity of 45.1 +22.3iul-1 (range 14.7-
66.2). Children receiving blood transfusions for
other disorders also showed transient serum DBH
elevations. The later rise in this patient was
considered a normal age-related manifestation
associated with increased sympathetic activity as
the child began to walk. The changes in DBH
activity seem to be unrelated to the amount of
residual tumour and the urinary catecholamine
output. In another patient (Case 26) DBH levels
were measured repeatedly from diagnosis to death
and at no time were they above those of the age-
matched control group; the DBH levels bore no
relationship to the tumour size or urinary
catecholamine output and fell prior to the child's
death with disseminated disease. Another patient
(Case 2) had a transient elevation in DBH
(66.3iul-1 compared with the control range of 0-
12.2iul- after a blood transfusion.
Discussion
The interpretation of serum DBH levels in children
is more difficult than in adults, in whom DBH
activity is not age-dependent and values are
generally higher. At birth serum DBH levels are
almost undetectable, but they rise during the first
years of life, and they reach adult values at 7-8
years (Weinshilboum, 1978). Evaluation of serum
DBH levels thus requires comparison with control
subjects of the same age group, measured by the
same assay.
Neuroblastoma cells, both human (De Potter et
al., 1974; Biedler et al., 1978) and mouse (Anagnoste
et al., 1972) contain DBH and catecholamines. In
phaeochromocytoma patients, elevated serum DBH
and urinary catecholamines fall after removal of the
tumour (Aunis & Bouclier, 1977). Neuroblastoma is
also associated with increased catecholamine
excretion. Serum DBH levels might thus be
expected to rise in these patients, too, especially in
those whose tumours secrete predominantly
noradrenalines. Of our 21 neuroblastoma patients
with active disease, one excreted excess of HMMA
only, 7 excreted excess amounts of total
catecholamines only, and 13 excreted 2 or more
metabolites in excess. All patients had DBH levels
similar to age-matched controls. The lack of
correlation between urinary metadrenaline excretion
and serum DBH may be due to biochemical
differences of neuroblastoma cells. In
sympathetically innervated tissue 2 types ofSERUM DOPAMINE ,B HYDROXYLASE IN NEUROBLASTOMA 119
K
LO
V
V
V
V
V
-C
v VV .01-
V -~~~~~~
l v V
v~~ ~ ~~~~~~o
V~~V
- -
~ ~~ -vv VV
V * /s .- V. --
V W vv
*0 . ** v
xi5* . Iv I I I-
68
66
40[-
I_
0
,30
a)
05
g0
-c
Cu
CL
o 201 0
10l
1 2 3 4 5 6 7 8 9
Age (yrs)
Figure 2 Serum DBH of control (V) and neuroblastoma (0) patients. C=Control P=Patients.120 B.B. ELDEEB et al.
Table III Serial serum DBH and urinary chatecholamines and metabolites (pgmg-' creatinine) on
neuroblastoma patients
Total
Age DBH Catecholamines Total
Case (years) Stage IU l-' (as Dopamine) Metadrenalines HMMA Clinical Status
4 0.8 I 0.4 2.77 1.14 9.80 NED
3.0 7.5 1.00 0.69 11.80 NED: walking
3.1 10.4 0.21 0.91 9.20 NED
3.2 10.3 0.83 0.79 11.80 NED
3.4 10.5 1.10 0.69 11.10 NED
3.7 13.8 1.33 1.10 10.80 NED
6 0.8 IV 2.8 16.101 0.90 9.30 Disease
0.8 13.1 - Postoperative transfusion
1.0 3.7 Disease
1.2 4.8 Disease
1.5 4.7 16.70T 1.10 7.96 Disease
1.6 9.2 Disease: walking
1.7 12.4 6.2 1.60 6.70 Disease
1.8 12.0 7.2 0.82 9.60 Disease
1.9 Died: neuroblastoma
9 1.2 IV 0.90 12.70T 6.70t 117.00T Disease
1.4 1.02 35.80t 5.60t 143.00T Disease
1.6 56.00T 3.70t 146.00T Disease
1.7 Died: neuroblastoma
12 1.8 III 3.30t - 14.40T Disease
2.0 4.90 1.20 0.77 4.40 NED
3.0 14.60 0.63 - 6.70 NED
7.8 Alive: NED
16 4.0 III 3.0 1.60 0.48 5.90 ? Disease
5.0 6.7 0.31 0.16 2.70 NED
5.7 8.1 0.58- 0.68 6.00 NED
6.0 6.9 0.78 0.58 5.30 NED
7.7 .- Alive: NED
21 4.4 IV 9.8 15.00t 14.40T 68.30T Disease
4.7 23.1 - - Disease
4.8 23.4 - Disease
5.3 26.7 . Disease
5.4 - - Died: neuroblastoma
25 5.4 IV 0.2 - NED
5.5 0.3 0.67 0.65 6.75 NED
5.6 0.5 0.80 0.41 8.20 NED
5.7 1.2 - Disease
5.8 Died: neuroblastoma
26 7.3 IV 19.4 1.10 1.06 12.40T Disease
7.7 19.2 0.56 0.49 4.40 NED
7.8 25.4 0.52 0.63 5.00 NED
8.1 27.5 NED
8.2 27.7 1.32 0.83 5.50 NED
8.3 26.5 - NED
8.6 22.1 5.60t 8.70T 37.30t Disease
8.7 Died: neuroblastomaSERUM DOPAMINE # HYDROXYLASE IN NEUROBLASTOMA 121
noradrenaline storage vesicles have been identified.
Only one of these contains DBH, the other
possessing little, if any, DBH activity.
Neuroblastoma cells lack enzyme-containing
vesicles (De Potter et al., 1974; 1978a). Studies of
subcellular distribution of catecholamines and
enzymes have shown that in both human (De
Potter et al., 1974) and mouse (De Potter et al.,
1978b; 1980) neuroblastoma, most of the DBH is
associated with the plasma membrane. This bound
DBH is not released by exocytosis.
In conclusion, our study has demonstrated that
any changes in serum DBH level observed in
neuroblastoma patients could be accounted for by
increasing age and physical activity or by blood
transfusion with adult blood containing higher
DBH activity than present in the patient. We found
no correlation with disease status or urinary
catecholamine excretion.
We thank the National Cancer Institute of Cairo
University and the Research Endowment Fund of the
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